Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Common Equity (2016 - 2026)

Perspective Therapeutics' Common Equity history spans 16 years, with the latest figure at $347.4 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 22.06% to $347.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $347.4 million, a 22.06% increase, with the full-year FY2025 number at $207.0 million, down 28.77% from a year prior.
  • Common Equity hit $347.4 million in Q1 2026 for Perspective Therapeutics, up from $207.0 million in the prior quarter.
  • Over the last five years, Common Equity for CATX hit a ceiling of $347.4 million in Q1 2026 and a floor of $54.6 million in Q4 2022.
  • Historically, Common Equity has averaged $186.7 million across 5 years, with a median of $207.0 million in 2025.
  • Biggest five-year swings in Common Equity: skyrocketed 286.63% in 2024 and later decreased 28.77% in 2025.
  • Tracing CATX's Common Equity over 5 years: stood at $54.6 million in 2022, then soared by 37.58% to $75.2 million in 2023, then skyrocketed by 286.63% to $290.7 million in 2024, then decreased by 28.77% to $207.0 million in 2025, then skyrocketed by 67.82% to $347.4 million in 2026.
  • Business Quant data shows Common Equity for CATX at $347.4 million in Q1 2026, $207.0 million in Q4 2025, and $242.2 million in Q3 2025.